1 week Ago By Defense World Staff
Envestnet Asset Management Inc. lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 13.
1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 32,115 shares of the biotechnology company’s stock after purchasing an additional 3,723 shares during the quarter. Envestnet Asset Management Inc.
owned 0.05% of Blueprint Medicines worth $2,801,000 at the end of the most recent reporting period. Several other institutional investors have also recently added to or reduced their stakes in BPMC.
Empirical Asset Management LLC acquired a new stake in Blueprint Medicines during the 4th quarter valued at $2,348,000. Stephens Inc. AR bought a new position in Blueprint Medicines in the 4th quarter valued at $321,000.
Bank of New York Mellon Corp increased its stake in shares of Blueprint Medicines by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock valued at $26,465,000 after buying an additional 7,101 shares during the period.
KBC Group NV raised its position in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 1,023 shares during the last quarter.
Finally, Raymond James Financial Inc. bought a new position in Blueprint Medicines in the fourth quarter valued at about $21,104,000. Insider Transactions at Blueprint MedicinesIn other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Monday, March 24th.
The stock was sold at an average price of $95.02, for a total value of $216,075.48.
Following the transaction, the chief operating officer now directly owns 69,266 shares of the company’s stock, valued at $6,581,655.32. This represents a 3.
18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction on Monday, March 3rd.
The stock was sold at an average price of $92.62, for a total value of $296,661.86.
Following the transaction, the insider now owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.
92 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.
21% of the company’s stock. Analysts Set New Price TargetsSeveral equities research analysts have recently commented on BPMC shares. Wedbush reiterated an “outperform” rating and set a $128.
00 price target on shares of Blueprint Medicines in a research report on Wednesday, April 16th. Morgan Stanley started coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They set an “equal weight” rating and a $100.
00 price target on the stock. Scotiabank started coverage on Blueprint Medicines in a report on Friday, March 7th. They issued a “sector outperform” rating and a $150.
00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Tuesday, April 8th.
Finally, Wolfe Research initiated coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company.
Based on data from MarketBeat, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $124.95.View Our Latest Report on BPMCBlueprint Medicines Stock Up 1.
8 %Shares of BPMC stock opened at $87.66 on Friday. The company has a debt-to-equity ratio of 1.
15, a quick ratio of 2.80 and a current ratio of 2.85.
Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $121.
90. The firm’s 50-day moving average is $87.57 and its 200-day moving average is $93.
10. The stock has a market cap of $5.60 billion, a price-to-earnings ratio of -81.
17 and a beta of 0.75. Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last released its quarterly earnings data on Thursday, February 20th.
The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.
11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.
19%. Sell-side analysts predict that Blueprint Medicines Co. will post -1.
28 EPS for the current year. About Blueprint Medicines (Free Report)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Read MoreFive stocks we like better than Blueprint MedicinesHow to Use the MarketBeat Stock Screener Short Sellers Gave Up on These 3 Names RecentlyTechnology Stocks Explained: Here’s What to Know About Tech3 Boring Stocks Outperforming the Market This YearHigh Flyers: 3 Natural Gas Stocks for March 2022If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyWant to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC – Free Report).
.
